Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Rhea-AI Summary

Palisade Bio (NASDAQ:PALI), a clinical-stage biopharmaceutical company developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

During the conference, CEO JD Finley shared insights about his career journey, his commitment to the company, and his enthusiasm for Palisade's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.

News Market Reaction – PALI

-9.20% 64.2x vol

37 alerts

-9.20% News Effect

+36.4% Peak Tracked

-16.2% Trough Tracked

-$656K Valuation Impact

$6M Market Cap

64.2x Rel. Volume

On the day this news was published, PALI declined 9.20%, reflecting a notable negative market reaction. Argus tracked a peak move of +36.4% during that session. Argus tracked a trough of -16.2% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $656K from the company's valuation, bringing the market cap to $6M at that time. Trading volume was exceptionally heavy at 64.2x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

– Video webcast now available on-demand

Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.

As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development.

The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page under the Investors section of the Company’s website (palisadebio.com).

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

When did Palisade Bio (PALI) participate in the Virtual Investor Summer Spotlight Conference?

Palisade Bio participated in the Virtual Investor Summer Spotlight Conference with the on-demand video webcast becoming available on July 22, 2025.

What therapeutic areas does Palisade Bio (PALI) focus on?

Palisade Bio focuses on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases.

Who is the CEO of Palisade Bio (PALI)?

JD Finley serves as the Chief Executive Officer of Palisade Bio.

Where can investors watch Palisade Bio's (PALI) conference presentation?

The presentation is available on-demand at virtualinvestorco.com and on the Events page in the Investors section of palisadebio.com.